Company Profile

Path Ex Inc
Profile last edited on: 9/23/21      CAGE: 7RD70      UEI: XFGZXJB2PC49

Business Identifier: Selective removal of pathogens - including multi-drug resistant bacteria, and endotoxins - from circulating blood
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

111 10th Avenue South Suite 105
Nashville, TN 37203
   (615) 938-7057
Location: Single
Congr. District: 05
County: Davidson

Public Profile

For patietnts diagnosed with sepsis, each hour delay before effective antibiotic treatment is provided, risk of death increases significantly. Hence, new approaches to suppress the systemic consequences of blood-borne bacteria and the endotoxins in the earliest stages of sepsis represent an urgent, unmet need with clear potential clinical impact. Currently resident in JLab Houston, Path Ex is structured around development of a technology that will remove pathogens and endotoxins to treat sepsis. The PATH EX device - designated CycloPE - is being developed to treat septic patients in the intensive care unit (ICU) setting of hospitals. The patient's blood continuously circulated through the CycloPE platform using a method similar to renal replacement therapy (i.e. hemodialysis or hemofiltration). Result: direct bacterial and endotoxin removal from patient -- a novel methodthat eliminates the time consuming, 2-day step of bacterial culture prior to bacterial identification. The firm's approach breaks the paradigm of current sepsis treatment protocols by rapidly eliminating the infectious agents, including multi-drug resistant variants, that lead to sepsis and sepsis progression – rather than applying non-specific and/or ineffective antibiotics. Path Ex's inertial-based fluidic platform can separate and immobilize bacteria from continuously flowing whole blood, avoiding obstacles to translation that limit blood purification therapies that utilize membrane-based column filters for removal of inflammatory mediators and other toxins from blood. The PATH EX technology can be used as a Class I diagnostic, rapidly capturing pathogens from blood samples. The captured pathogens can then be identified and analyzed using MALDI-TOF or PCR.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
Less than .5M
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2021 2 NSF $1,519,999
Project Title: Rapid Blood Cleansing Device to Combat Infection

Key People / Management

  Sinead E Miller -- CEO and Co-Founder

  Alex Wieseler -- COO